2. Agid O., Shapira B., Zislin J. et al. Environment and vulnerability to major psychiatric illness: a case control study of early parental loss in major depression, bipolar disorder and schizophrenia. Molecular Psychiatry 1999; 4: 163–172.
3. Akiskal H.S. The clinical necessity of a return to Kraepelin’s broad schema of manic depression. Psychiatric Clinics of North America 1999; 22: xi-xii.
4. Akiskal K.K., Akiskal H.S. The theoretical underpinnings of affective temperaments: implications for evolutionary foundations of bipolar disorder and human nature. Journal of Affective Disorders 2005; 85: 231–239.
5. Allilaire J.F., Hantouche E.G., Sechter D. et al. Frequency and clinical aspects of bipolar II disorder in a French multicenter study: EPIDEP L’Encephale 2001; 27: 149–158.
6. Altamura A.C., Salvadori D., Madaro D. et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. Journal of Affective Disorders 2003; 76: 267–271.
7. Amsterdam J.D, Shults J. Fluoxetine monotherapy of bipolar type II and bipolar NOS major depression: a double-blind, placebo-substitution, continuation study. International Clinical Psychopharmacology 2005; 20: 257–264.
8. Ando N., Morimoto K., Watanabe T. et al. Enhancement of central dopaminergic activity in the kainate model of temporal lobe epilepsy: implication for the mechanism of epileptic psychosis. Neuropsychopharmacology 2004; 29: 1251–1258.
9. Andreasen N.C. Creativity and mental illness: Prevalence rates in writers and their first-degree relatives. American Journal of Psychiatry 1987; 144: 1288–1292.
10. Andreasen N.C. Brave New Brain. Conquering Mental Illness in the Era of the Genome. Oxford University Press, Oxford, 2001.
11. Andreasen N.C. The Creating Brain. The Neuroscience of Genius. Dana Press, New York, 2005.
12. Angst J. Recurrent brief depression. A new concept of depression. Pharmacopsychiatry 1990; 23: 63–66.
13. Angst J. The emerging epidemiology of hypomania and bipolar II disorder. Journal of Affective Disorders 1998; 50: 143–151.
14. Angst J. Zur Ätiologie und Nosologie endogener depressiver Psychosen. Springer-Verlag, Berlin, 1966.
15. Angst J., Adolfsson R., Benazzi F. et al. The HCL-32: towards a selfassessment tool for hypo-manic symptoms in outpatients. Journal of Affective Disorders 2005; 88: 217–233.
16. Angst J., Gamma A., Lewinsohn P. The evolving epidemiology of bipolar disorder. World Psychiatry 2002; 1: 146–148.
17. Aphorisms by Hippocrates, Internet Classics Archive. http://classics.mit.edu/Hipocrates/ aphorisms.1.i.html
18. Arfvedson A. Untersuchungen einiger bei der Eisen Grube von Utö vorkommenden Fossilien und von einem darin gefundenen neuen feuerfesten Alkali. Schweiggers Journal für Chemie und Physik 1818; 22: 93-120.
19. Arystoteles. Dzieia wszystkie. Tom 4. Panstwowe Wydawnictwo Naukowe, Warszawa, 1990.
20. Baastrup P.C. The use of lithium in manic-depressive psychoses. Comprehensive Psychiatry 1964; 10: 396–408.
21. Baastrup P.C., Schou M. Lithium as a prophylactic agent. Its effect against recurrent depressions and manic-depressive psychosis. Archives of General Psychiatry 1967; 16: 162172.
22. Baillarger J. De la folie ä double forme. Annales Medico-Psychologiques 1854; 6: 367391.
23. Baldessarini R.J., Tondo L., Davis P. et al. Decreased risk of suicides and attempts during long-term lithium treatment: a meta-analytic review. Bipolar Disorders 2006; 8: 625–639.
24. Barraclough B. Suicide prevention, recurrent affective disorder and lithium. British Journal of Psychiatry 1972; 121: 391–392.
25. Barron F. Barron-Welsh Art Scale. A Portion of the Welsh Figure Preference Test. Consulting Psychologists Press, Palo Alto, California, 1963.
26. Bartrop R., Luckhurst E., Lazarus L. et al. Depressed lymphocyte function after bereavement. Lancet 1977; 1: 834–836.
27. Bauer M.S., Mitchner L. What is a «mood stabilizer»? An evidence-based response. American Journal of Psychiatry 2004; 161: 3-18.
28. Baum A.E., Akula N., Cabanero M. et al. A genome-wide association study implicates dia-cylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Molecular Psychiatry 2007; publikacja internetowa z 8 maja (przed drukiem w kolejnym numerze pisma).
29. Belmaker R.H., Livne A., Agam G. Role of inositol-1-phosphatase inhibition in the mechanism of action of lithium. Pharmacology and Toxicology 1990; 66 (Suppl 3): 76–83.
30. Berridge M.J , Downes C.P , Hanley M.R. Neural and developmental actions of lithium: a unifying hypothesis. Cell 1989; 59: 411–419.
31. Bilikiewicz T. Psychiatria kliniczna. Wyd. V popr. i uzup. Panstwowy Zakiad Wydawnictw Lekarskich, Warszawa, 1973.
32. Blader J.C., Carlson G.A. Increased rates of bipolar disorder diagnoses among U.S. child, adolescent, and adult inpatients, 1996–2004. Biological Psychiatry 2007; 62: 107–114.
33. Bleuler E. Dementia praecox oder Gruppe der Schizophrenien. Deuticke, Leipzig, 1911.
34. Blum K., Braverman E.R., Wu S. et al. Association of polymorphisms of dopamine D2 receptor (DRD2), and dopamine transporter (DAT1) genes with schizoid/avoidant behaviors (SAB). Molecular Psychiatry 1997; 2: 239–246.
35. Borkowska A., Rybakowski J.K. Neuropsychological frontal lobe tests indicate that bipolar depressed patients are more impaired than unipolar. Bipolar Disorders 2001; 3: 88–94.
36. Breggin P.R., Breggin G.R. Talking Back To Prozac: What Doctors Aren’t Telling You About Today’s Most Controversial Drug. St. Martins Press, New York, 1995.
37. Broszkiewicz J. Doktor Twardowski. Czytelnik, Warszawa, 1979.
38. Brown S.M., Hariri A.R. Neuroimaging studies of serotonin gene polymorphisms: exploring the interplay of genes, brain, and behavior. Cognitive and Affective Behavioral Neuroscience 2006; 6: 44–52.
39. Bunney W.E. Jr., Davis J.M. Norepinephrine in depressive reactions. A review. Archives of General Psychiatry 1965; 13: 483–494.
40. Burch G.S., Pavelis C., Hemsley D.R., Corr P.J. Schizotypy and creativity in visual artists. British Journal of Psychology 2006; 97: 177–190.
41. Burton R. The Anatomy of Melancholy. What it is: With all the Kinds, Causes, Symptoms and Several Cures of It. New York Review of Books, New York, 2001.
42. Cade J.F. Lithium salts in the treatment of psychotic excitement. Medical Journal of Australia 1949; 36: 349–352.
43. Calabrese J.R, Bowden CL, Sachs G et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. Journal of Clinical Psychiatry 2003; 64: 1013–1024.
44. Calabrese J.R., Keck P.E., Macfadden W. et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. American Journal of Psychiatry 2005; 162: 1351–1360.